dr. cabanillas on lenvatinib as first-line therapy for patients with dtc
Published 8 years ago • 446 plays • Length 0:48Download video MP4
Download video MP3
Similar videos
-
7:37
lenvatinib as up-front therapy for unresectable hcc
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
1:17
dr. marcia brose discusses lenvatinib as a new option in dtc
-
9:03
sequencing therapies for differentiated thyroid cancer
-
6:27
nccn guidelines for first-line treatment of rr-dtc
-
8:28
lenvatinib in advanced dtc
-
1:23
dr. brose discusses lenvatinib for the treatment of patients with thyroid cancer
-
1:00:02
papillary thyroid cancer in children & young adults: retrospective study with dr. wang
-
1:46
dr. bible on impact of lenvatinib on treatment landscape of dtc
-
1:59
dr. cohen on lenvatinib in first- or second-line thyroid cancer
-
1:02:53
neoadjuvant therapies for advanced thyroid cancers with dr. maria cabanillas
-
7:03
lenvatinib breakthrough designation, new drug applications for nsclc and sts, and more
-
6:47
lenvatinib: new kid on the block
-
1:28
dr. wirth on the use of lenvatinib in hypertensive patients with thyroid cancer
-
1:41
dr. armaghany on frontline sorafenib versus lenvatinib in unresectable hcc
-
2:41
leap-011: exploring first-line pembrolizumab lenvatinib for advanced urothelial carcinoma
-
1:39
dr. bastholt on lenvatinib in thyroid cancer
-
1:22
dr. cheng on phase iii findings of lenvatinib in hcc
-
1:32
three-arm trial of lenvatinib and everolimus for metastatic renal cell carcinoma